186 related articles for article (PubMed ID: 20489208)
21. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
[TBL] [Abstract][Full Text] [Related]
22. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
Gizatullin F; Yao Y; Kung V; Harding MW; Loda M; Shapiro GI
Cancer Res; 2006 Aug; 66(15):7668-77. PubMed ID: 16885368
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.
Chang LJ; Eastman A
Cancer Biol Ther; 2012 Sep; 13(11):1047-57. PubMed ID: 22825333
[TBL] [Abstract][Full Text] [Related]
24. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
25. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
[TBL] [Abstract][Full Text] [Related]
26. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.
Korotchkina LG; Leontieva OV; Bukreeva EI; Demidenko ZN; Gudkov AV; Blagosklonny MV
Aging (Albany NY); 2010 Jun; 2(6):344-52. PubMed ID: 20606252
[TBL] [Abstract][Full Text] [Related]
27. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
28. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
Shimazu K; Tada Y; Morinaga T; Shingyoji M; Sekine I; Shimada H; Hiroshima K; Namiki T; Tatsumi K; Tagawa M
BMC Cancer; 2017 May; 17(1):309. PubMed ID: 28464864
[TBL] [Abstract][Full Text] [Related]
29. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
30. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells.
Huang B; Deo D; Xia M; Vassilev LT
Mol Cancer Res; 2009 Sep; 7(9):1497-509. PubMed ID: 19737973
[TBL] [Abstract][Full Text] [Related]
33. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
34. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy.
Das M; Sahoo SK
Acta Biomater; 2011 Jan; 7(1):355-69. PubMed ID: 20727991
[TBL] [Abstract][Full Text] [Related]
35. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation.
Xia M; Knezevic D; Vassilev LT
Oncogene; 2011 Jan; 30(3):346-55. PubMed ID: 20871630
[TBL] [Abstract][Full Text] [Related]
36. P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.
Gunasegaran B; Neilsen PM; Smid SD
Toxicol In Vitro; 2020 Sep; 67():104908. PubMed ID: 32502622
[TBL] [Abstract][Full Text] [Related]
37. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
[TBL] [Abstract][Full Text] [Related]
38. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
[TBL] [Abstract][Full Text] [Related]
39. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
Kan CE; Patton JT; Stark GR; Jackson MW
Cancer Res; 2007 Oct; 67(20):9862-8. PubMed ID: 17942917
[TBL] [Abstract][Full Text] [Related]
40. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
